Activation of the A10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic
- 1 September 1988
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 154 (1) , 53-57
- https://doi.org/10.1016/0014-2999(88)90362-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Rimcazole (BW 234 U) and regional monoamine concentrations in mouse brainLife Sciences, 1987
- An endogenous ligand for the sigma opioid binding siteSynapse, 1987
- Rimcazole (BW 234U), a novel antipsychotic agent whose mechanism of action cannot be explained by a direct blockade of postsynaptic dopaminergic receptors in brainDrug Development Research, 1986
- Acute and subchronic effects of Rimcazole (BW 234U), a potential antipsychotic drug, on A9 and A10 dopamine neurons in the ratLife Sciences, 1986
- Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brainLife Sciences, 1986
- Effects of N-allylnormetazocine (skf 10,047), phencyclidine, and other psychomotor stimulants in the rat following 6-hydroxydopamine lesion of the ventral tegmental areaNeuropharmacology, 1986
- Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the ratNeuropharmacology, 1986
- The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activityEuropean Journal of Pharmacology, 1984
- Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose-range studyDrug Development Research, 1983
- BW234U,(cis-9-[3–(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agentJournal of Pharmacy and Pharmacology, 1982